With a serum potassium of 5.8 mmol/L, how should hyperkalaemia be managed?

Management of Potassium 5.8 mmol/L

With a potassium of 5.8 mmol/L (moderate hyperkalemia), you should immediately normalize the potassium level while identifying and correcting reversible precipitating factors, then implement long-term management to prevent recurrence rather than discontinuing life-saving medications like RAASi. 1

Immediate Assessment and Classification

A potassium of 5.8 mmol/L falls into the moderate hyperkalemia category (5.5-6.0 mmol/L) 2. This level requires urgent attention but is not immediately life-threatening unless accompanied by ECG changes or symptoms.

Critical First Steps:

1. Obtain an ECG immediately to identify cardiac conduction disturbances (peaked T waves, widened QRS, prolonged PR interval) 2, 3

   • ECG abnormalities may not correlate perfectly with potassium levels, but their presence mandates emergent treatment
   • Patients with CKD, diabetes, or heart failure often tolerate levels up to 6.0 mmol/L without arrhythmias 2

2. Rule out pseudohyperkalemia - repeat measurement if hemolysis suspected or blood drawn with prolonged tourniquet time 2

3. Assess for symptoms: muscle weakness, paralysis, palpitations 3

Acute Treatment Decision Algorithm

If ECG Changes Present OR Symptomatic:

Treat emergently with:

• IV calcium gluconate or chloride (membrane stabilization) 2
• Insulin with glucose (shift potassium intracellularly, effect lasts 1-4 hours) 2
• Beta-2 agonists (nebulized salbutamol - off-label in some countries) 2
• Sodium bicarbonate if metabolic acidosis present 2

Critical pitfall: These agents only provide temporary benefit (1-4 hours) and don't increase potassium excretion. Rebound hyperkalemia occurs after 2 hours, so initiate potassium-lowering agents immediately 2.

If Asymptomatic with Normal ECG (Most Common at 5.8):

Proceed directly to potassium normalization and cause identification 1

Identify and Correct Reversible Factors

Systematically evaluate:

• Medications: NSAIDs, potassium-sparing diuretics, trimethoprim, heparin 2
• Dietary intake: excessive potassium-rich foods, salt substitutes, herbal supplements 2
• Acute kidney injury: volume depletion, infection, contrast exposure
• Metabolic acidosis: correct with bicarbonate 2
• Tissue breakdown: rhabdomyolysis, tumor lysis, hemolysis

Potassium Normalization Strategy

The 2025 European guidelines emphasize that the initial aim is to normalize potassium levels, not simply monitor 1. For a level of 5.8 mmol/L:

First-Line Potassium Removal:

1. Loop diuretics (if adequate renal function and euvolemic/hypervolemic) 2

2. Potassium binders - newer agents preferred:

   • Sodium zirconium cyclosilicate (SZC) or Patiromer 1, 2, 3
   • These are more effective and safer than older resins (sodium polystyrene sulfonate associated with serious GI adverse effects) 3, 4
   • Can be used in both acute and chronic hyperkalemia 3

3. Hemodialysis only if:

   • End-stage renal disease present
   • Severe renal impairment with ongoing potassium release
   • Refractory to medical management 2

Critical Management Principle: DO NOT Discontinue RAASi

This is the most important clinical decision point. A potassium of 5.8 mmol/L should NOT trigger RAASi discontinuation 1, 2.

The Evidence:

• RAASi therapy reduces mortality and morbidity in cardiovascular disease 2
• Discontinuation increases risk of adverse cardiovascular and renal outcomes or death 5
• Clinical benefit of RAASi persists even with modest potassium elevations 2
• Only 51.5% of eligible patients with CKD/HF receive RAASi due to hyperkalemia concerns - this is suboptimal practice 6

Instead of Stopping RAASi:

1. Continue RAASi at current dose while treating hyperkalemia 1
2. Initiate potassium binder to enable continued RAASi therapy 1, 7
3. Only temporarily reduce RAASi dose if potassium remains >6.0 mmol/L despite binder therapy 2

Long-Term Management (Essential - Not Optional)

Unless the cause can be reversed, treatment for recurrent hyperkalemia is likely indefinite 1. At 5.8 mmol/L, this patient is at high risk for recurrence.

Ongoing Strategy:

1. Chronic potassium binder therapy (patiromer or SZC) while on RAASi 1, 7, 5

   • Recurrence rates reach 43.8% without structured management 7
   • Recurrent hyperkalemia associated with faster eGFR decline 7

2. Dietary counseling: restrict potassium intake to <3,000 mg/day 2, 5

3. Structured monitoring protocol:

   • Check potassium before initiating RAASi 5
   • Recheck 1-2 weeks after RAASi initiation or dose change 5
   • Then every 3 months for stable patients 8
   • Monthly for high-risk patients (eGFR <30, diabetes, elderly) 8

4. After normalization with binder, additional monitoring beyond routine comorbidity checks is not necessary 1

Common Pitfalls to Avoid

1. Discontinuing RAASi reflexively - this increases mortality 1, 2, 5
2. Using only dietary restriction - insufficient as monotherapy at this level 1
3. Relying on temporary measures (insulin, beta-agonists) without initiating definitive potassium removal 2
4. Using sodium polystyrene sulfonate - serious GI complications, newer binders preferred 3, 4
5. Failing to plan for long-term management - hyperkalemia recurs in one-third of patients 6, 7

Summary Algorithm

For K+ 5.8 mmol/L:

1. ECG + assess symptoms → If abnormal, treat emergently
2. Rule out pseudohyperkalemia
3. Identify reversible causes (meds, diet, AKI)
4. Normalize potassium: loop diuretic + potassium binder (SZC or patiromer)
5. Continue RAASi - do not discontinue
6. Long-term binder therapy + dietary modification + structured monitoring
7. Patient education on avoiding high-potassium foods and medication adherence

The goal is normokalemia (3.5-5.0 mmol/L) while maintaining optimal guideline-directed medical therapy for underlying cardiorenal disease 1, 8.